Fortius Clinic

fortiusclinic.com

Fortius Clinic is the UK's leading orthopaedic and sports medicine group. Founded by doctors and surgeons in 2011, with a shared vision to create a truly extraordinary centre of excellence in the diagnosis and treatment of musculoskeletal medicine. Fortius has over 80 leading specialist surgeons and physicians across orthopaedics, radiology, rheumatology and sports and exercise medicine. We have established a worldwide reputation for sports injuries, becoming the clinic of choice for many of the UK’s elite sports professionals, and since 2015 we have been accredited as a FIFA Medical Centre of Excellence (FMARC).

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

GREATER CFDNA RECOVERY MAY HELP ACCELERATE DEVELOPMENT OF CANCER LIQUID BIOPSY APPLICATIONS

PHASE Scientific | June 22, 2020

news image

PHASE Scientific, a high-growth biotechnology company that develops innovative sample preparation technologies, announced new findings at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II. The study presented by MD Anderson Cancer Center evaluates the efficacy of PHASE Scientific's liquid phase DNA isolation method (PHASIFY™) in improving cancer liquid biopsy sensitivity.Early-stage cancer diagnostics and cancer screening applications are limited ...

Read More

CELL AND GENE THERAPY

TEVARD BIOSCIENCES AND ZOGENIX COLLABORATES TO IDENTIFY AND DEVELOP NOVEL TRNA-BASED GENE THERAPIES FOR DRAVET SYNDROME AND OTHER GENETIC EPILEPSIES

Tevard Biosciences | December 04, 2020

news image

Tevard Biosciences, a privately-held biotechnology organization pioneering tRNA-based gene therapies, and Zogenix, a worldwide biopharmaceutical organization creating and commercializing uncommon infection treatments, today reported that the organizations have gone into a cooperation to recognize and create novel tRNA-based quality treatments for Dravet syndrome and other genetic epilepsies. Under the collaboration, Tevard will use its two interesting tRNA-based discovery platform...

Read More

MINIPCR BIO ANNOUNCES LAUNCH OF THE GELATO™ AN INTEGRATED DNA ANALYSIS SYSTEM

miniPCR bio | September 09, 2020

news image

miniPCR bio, a manufacturer of scientific tools for educators and researchers, today announced the launch of the GELATO™, an integrated DNA analysis system. GELATO™ combines gel electrophoresis with transillumination technology, allowing for simultaneous nucleic acid separation and visualization in a single, compact system. As a maker of innovative biotechnology for demanding settings, miniPCR bio has pioneered the development of tools that combine analytical power with the durabilit...

Read More

REVITOPE, JUNSHI BIOSCIENCES ENTER INTO RESEARCH COLLABORATION TO DEVELOP FIRST-IN-CLASS DUAL-ANTIGEN TARGETING CANCER THERAPIES

Revitope Oncology | July 14, 2020

news image

Revitope Oncology Inc ("Revitope Oncology")., a biotechnology company advancing a new class of precision cancer immunotherapies, its wholly-owned subsidiary Revitope Limited (Revitope Limited, together with Revitope Oncology, "Revitope") and Junshi Biosciences (1877.HK, 688180.SH), a leading innovation–driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced the companies have entered into a stra...

Read More
news image

GREATER CFDNA RECOVERY MAY HELP ACCELERATE DEVELOPMENT OF CANCER LIQUID BIOPSY APPLICATIONS

PHASE Scientific | June 22, 2020

PHASE Scientific, a high-growth biotechnology company that develops innovative sample preparation technologies, announced new findings at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II. The study presented by MD Anderson Cancer Center evaluates the efficacy of PHASE Scientific's liquid phase DNA isolation method (PHASIFY™) in improving cancer liquid biopsy sensitivity.Early-stage cancer diagnostics and cancer screening applications are limited ...

Read More
news image

CELL AND GENE THERAPY

TEVARD BIOSCIENCES AND ZOGENIX COLLABORATES TO IDENTIFY AND DEVELOP NOVEL TRNA-BASED GENE THERAPIES FOR DRAVET SYNDROME AND OTHER GENETIC EPILEPSIES

Tevard Biosciences | December 04, 2020

Tevard Biosciences, a privately-held biotechnology organization pioneering tRNA-based gene therapies, and Zogenix, a worldwide biopharmaceutical organization creating and commercializing uncommon infection treatments, today reported that the organizations have gone into a cooperation to recognize and create novel tRNA-based quality treatments for Dravet syndrome and other genetic epilepsies. Under the collaboration, Tevard will use its two interesting tRNA-based discovery platform...

Read More
news image

MINIPCR BIO ANNOUNCES LAUNCH OF THE GELATO™ AN INTEGRATED DNA ANALYSIS SYSTEM

miniPCR bio | September 09, 2020

miniPCR bio, a manufacturer of scientific tools for educators and researchers, today announced the launch of the GELATO™, an integrated DNA analysis system. GELATO™ combines gel electrophoresis with transillumination technology, allowing for simultaneous nucleic acid separation and visualization in a single, compact system. As a maker of innovative biotechnology for demanding settings, miniPCR bio has pioneered the development of tools that combine analytical power with the durabilit...

Read More
news image

REVITOPE, JUNSHI BIOSCIENCES ENTER INTO RESEARCH COLLABORATION TO DEVELOP FIRST-IN-CLASS DUAL-ANTIGEN TARGETING CANCER THERAPIES

Revitope Oncology | July 14, 2020

Revitope Oncology Inc ("Revitope Oncology")., a biotechnology company advancing a new class of precision cancer immunotherapies, its wholly-owned subsidiary Revitope Limited (Revitope Limited, together with Revitope Oncology, "Revitope") and Junshi Biosciences (1877.HK, 688180.SH), a leading innovation–driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced the companies have entered into a stra...

Read More